<DOC>
	<DOCNO>NCT01602588</DOCNO>
	<brief_summary>There emerge evidence hydroxychloroquine ( HCQ ) , drug use commonly prevention/ treatment malaria , rheumatoid arthritis lupus erythematosus , may improve survival outcome variety cancer include HGG , side effect . In trial investigator wish investigate whether treatment radiotherapy hydroxychloroquine effective treatment radiotherapy alone .</brief_summary>
	<brief_title>A Randomised Trial Investigating Additional Benefit Hydroxychloroquine ( HCQ ) Short Course Radiotherapy ( SCRT ) Patients Aged 70 Years Older With High Grade Gliomas ( HGG )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Hydroxychloroquine</mesh_term>
	<criteria>Male female patient age ≥70 yr identify neurooncology MDT . A histological diagnosis HGG , either biopsy resection . A life expectancy &gt; 2 month An ECOG performance status 0/1 Absolute neutrophil count ≥ 1.5 x 109 Platelet count ≥ 100 x 109 Bilirubin ≤ 1.5 mg/dL ( ≤ 25.6 µmol/L ) Creatinine ≤ 2 time upper limit normal ( ULN ) ALT AST ≤ 4 time ULN Mini Mental Status Exam score ≥ 17 ( Appendix 10 ) Written informed consent Ready start radiotherapy within 4 week surgery Concurrent psoriasis unless disease well control patient care specialist disorder agree monitor exacerbation Prior macular degeneration diabetic retinopathy Concurrent serious infection medical illness would preclude study therapy Another malignancy within past 5 year except curatively treat carcinoma situ basal cell carcinoma skin Porphyria Glucose 6 phosphate dehydrogenase ( G6PD ) deficiency Alcoholic liver disease Any concurrent severe/uncontrolled medical condition Currently take amiodarone Prior radiotherapy , chemotherapy , immunotherapy , biologic agent ( e.g. , immunotoxins , immunoconjugates , antisense agent , peptide receptor antagonist , interferon , interleukin , tumourinfiltrating lymphocyte , lymphokineactivated killer cell therapy , gene therapy ) , hormonal therapy brain tumour Prior polifeprosan 20 carmustine implant ( Gliadel wafer ) GliaSite® brachytherapy Concurrent cytochrome P450 enzymeinducing anticonvulsant drug ( e.g. , phenytoin , carbamazepine , phenobarbital , primidone , oxcarbazepine ) Other concurrent chemotherapeutic investigational agent cancer ( Concurrent glucocorticoid allow Documented side effect chloroquine relate agent . Unable give inform consent Patients history psychological illness condition opinion investigator may adversely affect compliance study medication</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>